Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02613273 · ClinicalTrials.gov registry record · NA
CHAMP: A Randomized Controlled Trial of High-intensity Aerobic and Resistance Exercise for Metastatic Prostate Cancer
A NA study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- NA
- Development phase
- 28
- Enrollment target
NCT02613273 is a NA study that has completed, run by University of California, San Francisco. The registered enrollment target is 28 participants.
The verdict
NCT02613273, a NA study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- NA
- Development phase
- 28 participants
- Enrollment target
Study Summary
This Phase II, open-label, three-arm randomized controlled trial (RCT) will investigate the effects of 12 weeks of aerobic exercise vs. 12 weeks of resistance exercise vs. usual care in men with metastatic castration resistant prostate cancer to determine the safety, feasibility, and tolerance of exercise; quality of life indicators, and a prognostic score.
Interventions
- BEHAVIORAL Experimental: Arm 1 (Aerobic Exercise)
- BEHAVIORAL Experimental: Arm 2 (Resist. Exercise)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2016-07-18 |
| Est. Completion | 2022-06-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02613273
The ClinicalTrials.gov registry entry for NCT02613273 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Experimental: Arm 1 (Aerobic Exercise) is the first listed.
NCT02613273 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02613273 about?
NCT02613273 is a clinical study titled "CHAMP: A Randomized Controlled Trial of High-intensity Aerobic and Resistance Exercise for Metastatic Prostate Cancer". This Phase II, open-label, three-arm randomized controlled trial (RCT) will investigate the effects of 12 weeks of aerobic exercise vs. 12 weeks of resistance exercise vs. usual care in men with metastatic castration resistant prostate cancer to determine the safety, feasibility, and tolerance of ex...
What is the current status of trial NCT02613273?
This trial is currently completed. It is a NA study. The enrollment target is 28 participants. The study started on 2016-07-18. Estimated completion is 2022-06-30.
What interventions are being tested in trial NCT02613273?
The interventions under investigation include: Experimental: Arm 1 (Aerobic Exercise) (BEHAVIORAL), Experimental: Arm 2 (Resist. Exercise) (BEHAVIORAL).
Who is sponsoring clinical trial NCT02613273?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.